huCD7/huCD19 Mouse
Product Name
huCD7/huCD19 Mouse
Product ID
C002127
Strain Name
C57BL/6Cya-Cd7tm1(hCD7)Cd19em3(hCD19)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huCD7/huCD19 Mouse (Catalog C002127) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Gene Name
CD7 & CD19
Gene Alias
GP40, TP41, Tp40, LEU-9, B4, CVID3
NCBI ID
Chromosome
Chr 17 (Human), Chr 16 (Human)
Datasheet
Strain Description
CD7 is mainly expressed in T cells and natural killer (NK) cells. It is expressed throughout thymocyte development from early stages to mature T cells, and also in some hematopoietic progenitor cells, but its expression level is low in most normal non-T-cell and non-NK-cell tissues. Abnormal expression or signaling dysregulation of CD7 is closely associated with various diseases. As an important target for immunotherapy, CD7 has become a key molecule for targeting T-cell malignancies due to its high expression in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and other T-cell malignant tumors [1]. The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B-cell receptor (BCR) signaling pathway, it is essential for B-cell development, activation, and differentiation. CD19 is a pan-B-cell marker, expressed only in the B-cell lineage, and is stably expressed throughout B-cell development (from pre-B cells to mature B cells and memory B cells). CD19 is a positive regulatory factor for BCR signal transduction. This protein forms a B-cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B-cell activation [2]. Dysregulation of CD19 is closely related to autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), manifesting as impaired B-cell differentiation and hypogammaglobulinemia. Due to its B-cell-specific expression, CD19 has become an important target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., tisagenlecleucel) has shown significant efficacy in refractory or relapsed acute lymphoblastic leukemia [3]. Recent studies have also explored bispecific antibodies targeting CD19 (e.g., blinatumomab) to enhance the clearance of tumor cells [4].
The huCD7/huCD19 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD19 mouse (Catalog No.: C001731). This model can be used for studying the immune mechanisms of CD7/CD19-related malignancies, as well as for screening, efficacy evaluation, and safety assessment of drugs targeting CD7/CD19.
Reference
Saha A, Jhaveri K, Sarfraz H, Chavez JC. Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. Expert Opin Biol Ther. 2023 Jul-Dec;23(9):869-876.
Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016 May;57(5):1021-32.
Freiwan A, Zoine JT, Crawford JC, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684-2696.
Komura K. CD19: a promising target for systemic sclerosis. Front Immunol. 2024 Oct 3;15:1454913.
Strain Strategy
The huCD7/huCD19 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD19 mouse (Catalog No.: C001731).
Figure 1. Gene editing strategy of huCD7 mice. The mouse Cd7 endogenous signal peptide and extracellular domain were replaced with the human CD7 signal peptide and extracellular domain. The expression of mouse Gm11775 would be affected by this KI region.
Figure 2. Gene editing strategy of huCD19 mice. The sequences from the start codon to partial intron 4 of the mouse Cd19 gene were replaced with the sequences from the start codon to partial intron 4 of the human CD19 gene.
Application Area
Research on tumor immune mechanisms related to CD7/CD19;
Screening, efficacy evaluation, and safety assessment of CD7/CD19-targeted drugs.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.